RxDoctor Payments Data

Jonathan Leon-Rosen, MD

Ophthalmology · St Thomas, VINPI 1376681536

Payments from drug & device makers

$3,229in general payments, 2019–2025

Across 114 payments — averaging $28.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$950
  • Amgen$594
  • AbbVie$399
  • NEW World Medical,inc.$211
  • Bausch & Lomb Americas Inc.$188
  • Oyster Point Pharma, Inc.$152
  • plus $735 from 14 others

What the payments were for

  • Food & beverage$3,221100%
  • Education$80%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few ophthalmology providers in U.S. Virgin Islandsto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$176,698
Medicare patients
368
Services billed
1,469

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine411$300,516
Cyclosporine63$27,496
MieboPerfluorohexyloctane/Pf26$19,635
BotoxOnabotulinumtoxina28$18,074
Prednisolone Acetate415$16,157
XiidraLifitegrast18$15,270
Latanoprost528$12,403
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat380$8,754
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha507$6,124
Ketorolac Tromethamine211$5,809
Timolol Maleate180$5,447
TobradexTobramycin/Dexamethasone17$4,627
MoxifloxacinMoxifloxacin Hcl175$4,469
Travoprost31$3,758
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol32$3,405

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Botox$399$318,590439 claims
Bausch & Lomb Americas Inc.Miebo, Xiidra$188$34,90644 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few ophthalmology providers in U.S. Virgin Islandson file to place this against a meaningful peer group, so we don't.

Other ophthalmology in St Thomas

Where these figures come from

Is this you, or does something look wrong? →